| |NOVEMBER 20269HHS PEPTIDE COMPOUNDING POLICY: WHAT CHANGES?DOP'S RS 7,000 CR BULK DRUG PLI SCHEME: WHAT'S CHANGING?ASTRAZENECA ACQUIRES OMNIOSE TO EXPAND BACTERIAL VACCINE PIPELINEPeptide compounding is entering a new phase in the United States. The Department of Health and Human Services (HHS) announced an interim enforcement-discretion policy covering six peptide substances used by 503A compounders. The policy means HHS does not intend to take enforcement action against state-licensed pharmacies, federal facilities or licensed physicians using the listed ingredients, provided they meet specified conditions.The move comes as telehealth company Hims & Hers prepares to expand its peptide offerings and manufacture BPC-157 and TB-500 domestically, renewing attention to oversight, product quality and patient safety. It covers specified forms and The bulk drug PLI scheme is set for a proposed Rs 7,000 crore revamp as the Department of Pharmaceuticals looks to address India's domestic pharmaceutical manufacturing challenges. The proposed program follows the underwhelming production and incentive disbursement performance of the existing Rs 6,940 crore scheme, despite manufacturers reporting significant investments. By June 2026, investments from the previous scheme had reached Rs 5,210.74 crore, while production stood at Rs 3,270 crore against a lifecycle target of Rs 37,378 crore.The revised framework is expected to introduce platform-based incentives, support brownfield manufacturing facilities and strengthen research capabilities to improve India's bulk drug production ecosystem. The bulk drug PLI scheme is being reconsidered as the Department of Pharmaceuticals (DoP) prepares a proposed Rs 7,000 crore program to strengthen domestic pharmaceutical manufacturing. The proposed framework follows gaps in the existing Rs 6,940 crore scheme, which attracted investments but struggled to translate them into production and incentive disbursements. POAstraZeneca is strengthening its bacterial vaccine pipeline through the acquisition of US biotechnology company Omniose. This move expands its vaccine research capabilities and opens new opportunities in bacterial vaccine development. As antimicrobial resistance (AMR) increasingly complicates the treatment of bacterial infections, pharmaceutical companies are exploring preventive approaches that could reduce the burden of infectious diseases.Omniose brings specialized bioconjugation technology that could help AstraZeneca develop next-generation vaccines. Omniose brings a proprietary bioconjugation platform that supports the development of conjugate vaccines. The technology links bacterial polysaccharides with carrier proteins, helping researchers develop vaccine candidates that target bacterial infections. This acquisition builds on the companies' previous research collaboration, allowing AstraZeneca to extend an established relationship while expanding its bacterial vaccine pipeline. POseeking diagnosis and treatment. Even when individuals recognize symptoms, they may struggle to find appropriate support or afford consultations and therapy. A UNICEF-India roundtable highlighted how sensational and inaccurate media coverage can reinforce stereotypes and discourage people from seeking assistance. Reporting that reduces complex mental health conditions to a single cause or portrays them negatively can deepen misconceptions rather than encourage understanding. POroutes of administration, rather than unrestricted use, and applies to compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act while HHS and the FDA develop the 503A bulk list. HHS says the approach is intended to expand and improve patient access to peptides. PO
< Page 8 | Page 10 >